Home / Market News / $ZVRA
benzinga Corporate Catalyst Impact 55/100 ● positive

Citizens Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $28

Aug 6, 2026, 1:14 PM UTC · Primary ticker $ZVRA

Citizens analyst Jason N. Butler has reiterated a Market Outperform rating on Zevra Therapeutics and increased its price target from $25 to $28. This indicates a positive outlook from the analyst, suggesting potential upside for the stock.

Citizens analyst Jason N. Butler has maintained a 'Market Outperform' rating on Zevra Therapeutics and raised the price target from $25 to $28. This action signals increased confidence from the analyst in ZVRA's future performance and valuation. For traders, this could be seen as a positive signal, potentially leading to short-term upward momentum or reinforcing long-term bullish sentiment. The primary impact is on Zevra Therapeutics, as the analyst's revised target suggests a higher perceived intrinsic value for the company's stock. While not a direct corporate action, analyst upgrades and price target increases can influence investor sentiment and trading activity.

$ZVRA positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.